Molly Billstein Leber, PharmD, BCPS, FASHP: Interchangeability Laws, Substitution, and the Future Role of Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP, discusses current features of state-level legislation on interchangeable biosimilars, approaches to using biosimilars in health systems, and the future role of biosimilars in patient care.
March 25, 2019
View Text Version

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.